SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Vestis Corporation (NYSE:VSTS) securities between May 2, 2024 and May 6, 2025. Vestis is a North American company that provides uniform rentals and workplace supplies across the U.S. and Canada. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigati ...

SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired PepGen Inc. (NASDAQ:PEPG) securities between March 7, 2024 and March 3, 2025. PepGen is a clinical-stage biotechnology company that focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The Company’s lead product candidate was PGN-EDO51, a proprietary enhanced deliv ...

Core Viewpoint - A securities class action lawsuit has been filed against Sarepta Therapeutics, Inc. due to allegations of misleading statements regarding the safety and efficacy of its treatment ELEVIDYS, which has been linked to severe adverse events including patient deaths [1][2]. Group 1: Allegations and Lawsuit Details - The lawsuit claims that Sarepta failed to disclose significant safety risks associated with ELEVIDYS, including severe side effects that were not detected during clinical trials [2]. - The class period for the lawsuit is defined as between June 22, 2023, and June 24, 2025, during which investors acquired Sarepta securities [1]. Group 2: Impact of Adverse Events on Stock Price - On March 18, 2025, Sarepta reported a patient death due to acute liver failure linked to ELEVIDYS, resulting in a stock price drop of over 27% [3]. - Following the announcement on April 4, 2025, regarding regulatory scrutiny and the halting of recruitment in some clinical studies, Sarepta's stock fell more than 7% [4]. - A second patient death was reported on June 15, 2025, leading to a suspension of ELEVIDYS shipments and a further stock decline of over 42% [5]. - The FDA issued a Safety Communication on June 24, 2025, regarding the investigation into acute liver failure cases, causing an additional stock drop of more than 8% [6]. Group 3: Investor Actions - Investors who purchased Sarepta shares are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline of August 25, 2025, to discuss their rights and interests in the class action [7].

NEW YORK, June 27, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Open Lending Corporation (NASDAQ: LPRO) between February 24, 2022 and March 31, 2025, both dates inclusive (the "Class Period"), of the important June 30, 2025 lead plaintiff deadline.So what: If you purchased Open Lending securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangemen ...

NEW YORK, June 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Red Cat Holdings, Inc. (NASDAQ: RCAT) between March 18, 2022 and January 15, 2025, both dates inclusive (the “Class Period”), of the important July 22, 2025 lead plaintiff deadline. SO WHAT: If you purchased Red Cat securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement ...

Core Viewpoint - Iovance Biotherapeutics Inc. is undergoing a leadership transition with the resignation of CFO Jean-Marc Bellemin amid commercial challenges and a class-action lawsuit related to its flagship drug Amtagvi [1][2][3]. Group 1: Leadership Transition - CFO Jean-Marc Bellemin will resign effective July 10, 2025, to pursue other endeavors, having held the position since November 2020 [1][2]. - The company has not yet named a successor for the CFO role, creating uncertainty during a challenging period [2]. Group 2: Commercial Challenges - Iovance's first-quarter sales for Amtagvi significantly underperformed expectations, leading to a revision of full-year revenue projections [3]. - The company attributed its disappointing results to "recent launch dynamics," including slow treatment timelines and higher-than-expected patient drop-off rates [6]. Group 3: Legal Issues - Iovance is facing a class-action lawsuit alleging securities fraud related to its portrayal of authorized treatment centers (ATCs) that are essential for administering Amtagvi [4][5]. - The lawsuit claims that the company misrepresented the operational efficiency of ATCs, which were reportedly experiencing delays and inefficiencies [5]. Group 4: Market Reaction - Following the disclosure of underwhelming first-quarter results and revised revenue guidance, Iovance's stock fell over 44%, from $3.17 to $1.75 per share within a day [7].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Hims & Hers Health, Inc. common stock during the specified Class Period, alleging misleading statements and failures to disclose critical information regarding partnerships and product offerings [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to common stock purchases of Hims & Hers Health, Inc. between April 29, 2025, and June 23, 2025 [1]. - The lawsuit claims that Hims made false and misleading statements about its collaboration with Novo Nordisk A/S, particularly regarding the availability of the weight-loss drug Wegovy and compounded semaglutide products [5]. - Investors are encouraged to join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by August 25, 2025, to represent the class in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Hims & Hers Health, Inc. due to allegations of misleading statements and illegal practices that have led to significant investor losses [2][4]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $50,000 in Hims between April 29, 2025, and June 22, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Hims, with a deadline of August 25, 2025, for investors to seek the role of lead plaintiff [2][6]. - The complaint alleges that Hims engaged in deceptive practices, including the promotion and sale of illegitimate versions of Wegovy®, which jeopardized patient safety [4]. Group 2: Partnership Termination and Stock Impact - On June 23, 2025, Novo Nordisk announced the termination of its partnership with Hims, citing violations of laws regarding the sale of compounded drugs and deceptive marketing practices [5]. - Following the announcement, Hims' stock price plummeted by $22.24, or 34.6%, closing at $41.98 per share, resulting in significant financial harm to investors [5]. Group 3: Call for Information - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Hims' conduct to support the investigation [7].

Core Viewpoint - A class action lawsuit has been filed against Reddit, Inc. for allegedly misleading investors regarding user growth and advertising revenue, particularly in light of changes to Google's search algorithm that negatively impacted Reddit's traffic [3][4]. Group 1: Class Action Details - The class action represents investors who purchased Reddit securities between October 29, 2024, and May 20, 2025, with a deadline of August 18, 2025, to file a lead plaintiff motion [1]. - The lawsuit claims that Reddit made false statements and failed to disclose material information about the impact of Google's algorithm changes on user traffic [3]. Group 2: Allegations Against Reddit - Key allegations include that changes to Google Search's algorithm, such as the introduction of AI Overview, significantly reduced user click-throughs to Reddit [3]. - It is alleged that the increase in searches for "Reddit" did not indicate genuine user intent to visit the site, as users were finding answers directly on Google [3]. - The lawsuit asserts that these factors led to a significant drop in traffic that Reddit could not quickly offset, undermining its guidance on user growth and advertising revenue [3]. Group 3: Financial Impact - Following the release of Q1 2025 financial results on May 1, 2025, which showed a third consecutive quarter of slowing daily active user growth, Reddit's stock price declined [4]. - Analysts from Wells Fargo downgraded Reddit's stock on May 19, 2025, lowering the price target to $115 due to concerns over Google's AI features causing permanent disruption to user traffic [4]. - Baird analysts also downgraded Reddit's stock on May 21, 2025, cutting the price target to $120, citing ongoing U.S. user growth headwinds, which resulted in a stock decline of over 9% [5].

Core Viewpoint - Rocket Pharmaceuticals is facing a class action lawsuit due to allegations of misleading investors regarding the safety and protocol of its clinical trials for gene therapies [3][4]. Group 1: Company Overview - Rocket Pharmaceuticals is a late-stage biotechnology company focused on developing gene therapies for rare and serious diseases [2]. Group 2: Legal Allegations - The class action lawsuit claims that Rocket Pharmaceuticals provided updates on its Phase 2 trial of RP-A501 for Danon disease while making materially false statements and omitting critical adverse facts about the trial's safety [3]. - The lawsuit alleges that the company was aware of the risk of Serious Adverse Events (SAEs), including patient deaths, but did not fully inform investors [3]. - It is claimed that Rocket Pharmaceuticals amended the trial protocol to include a new immunomodulatory agent without disclosing this change to shareholders [3]. Group 3: Impact of FDA Action - On May 27, 2025, Rocket Pharmaceuticals announced that the U.S. FDA had placed a clinical hold on the RP-A501 Phase 2 trial following the death of a participant treated under the amended protocol, which had not been disclosed to investors [4]. - Following this announcement, Rocket Pharmaceuticals' stock price experienced a decline [4].